A #2 global spine leader building a robotics-led implant flywheel—now expanded into neuromodulation—at a valuation still discounting its post-merger margin and cash-flow inflection.
Overview
Globus Medical (GMED) is a global musculoskeletal technology leader that has evolved from a spine-implant specialist (founded 2003) into a diversified spine/orthopedics/robotics and neuromodulation platform. The company is now estimated to hold ~23% share of the ~$11B global spine market, positioning it as the clear #2 player behind Medtronic and ahead of other large orthopedic competitors. Its core Musculoskeletal Solutions segment spans traditional and minimally invasive spine implants, trauma and joint reconstruction, and regenerative biomaterials (including proprietary Advanced Materials Science manufacturing). A key differentiator is Enabling Technologies: the Excelsius robotics/navigation/imaging ecosystem monetizes high-value capital placements and, more importantly, drives recurring implant/disposable “pull-through” via a razor-and-blade model. The 2023 NuVasive merger materially increased scale and sales coverage, while the April 2025 Nevro acquisition added the Senza spinal cord stimulation system—expanding Globus into chronic pain management and creating a broader continuum of care (pre-surgery pain, structural fusion, post-surgery pain). The company sells primarily through a large U.S. direct sales force and a mix of direct/distributor channels internationally, targeting surgeons, hospitals, and ASCs with both recurring consumables and lumpy capital equipment.